ArticlePloS one2012
Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.International journal of molecular sciences · 2018Pooled it
- Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.The pharmacogenomics journal · 2016Trial
- Synaptic protein expression in bipolar disorder patient-derived neurons implicates PSD-95 as a marker of lithium response.Neuropharmacology · 2025Article
- Pharmacogenomics and response to lithium in bipolar disorder.Pharmacogenomics · 2024Review
- Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms.The pharmacogenomics journal · 2021Article
- The anti-aging effects of lithium in lymphoblastoid cell lines from patients with bipolar disorder and controls.Journal of psychiatric research · 2020Article
- Identifying novel associations in GWAS by hierarchical Bayesian latent variable detection of differentially misclassified phenotypes.BMC bioinformatics · 2020Article
- Lithium response in bipolar disorder correlates with improved cell viability of patient derived cell lines.Scientific reports · 2020Article
- Differential Expression of Synapsin I and II upon Treatment by Lithium and Valproic Acid in Various Brain Regions.The international journal of neuropsychopharmacology · 2018Article
- The Role of Synapsins in Neurological Disorders.Neuroscience bulletin · 2018Review
- Distinct lithium-induced gene expression effects in lymphoblastoid cell lines from patients with bipolar disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2017Article
- Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.CNS drugs · 2016Review
- Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder.Molecular psychiatry · 2016Article
- Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014.Psychiatric genetics · 2016Article
- Brain oscillations in bipolar disorder and lithium-induced changes.Neuropsychiatric disease and treatment · 2016Review
- Role of presynaptic phosphoprotein synapsin II in schizophrenia.World journal of psychiatry · 2015Article
- Novel integrative genomic tool for interrogating lithium response in bipolar disorder.Translational psychiatry · 2015Article
- H3K4 tri-methylation in synapsin genes leads to different expression patterns in bipolar disorder and major depression.The international journal of neuropsychopharmacology · 2013Article
- Epigenetic regulation of synapsin genes in mood disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Review
- Ankyrin 3: genetic association with bipolar disorder and relevance to disease pathophysiology.Biology of mood & anxiety disorders · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
Bipolar disorder (BD) is a debilitating psychiatric condition with a prevalence of 1-2% in the general population that is characterized by severe episodic shifts in mood ranging from depressive to manic episodes. One of the most common treatments is lithium (Li), with successful response in 30-60% of patients. Synapsin II (SYN2) is a neuronal phosphoprotein that we have previously identified as a possible candidate gene for the etiology of BD and/or response to Li treatment in a genome-wide linkage study focusing on BD patients characterized for excellent response to Li prophylaxis. In the present study we investigated the role of this gene in BD, particularly as it pertains to Li treatment. We investigated the effect of lithium treatment on the expression of SYN2 in lymphoblastoid cell lines from patients characterized as excellent Li-responders, non-responders, as well as non-psychiatric controls. Finally, we sought to determine if Li has a cell-type-specific effect on gene expression in neuronal-derived cell lines. In both in vitro models, we found SYN2 to be modulated by the presence of Li. By focusing on Li-responsive BD we have identified a potential mechanism for Li response in some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.